Last $2.07 USD
Change Today -0.08 / -3.72%
Volume 437.8K
RIGL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

rigel pharmaceuticals inc (RIGL) Snapshot

Open
$2.12
Previous Close
$2.15
Day High
$2.21
Day Low
$2.07
52 Week High
03/17/14 - $5.00
52 Week Low
10/22/14 - $1.56
Market Cap
181.7M
Average Volume 10 Days
262.6K
EPS TTM
$-0.97
Shares Outstanding
87.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RIGEL PHARMACEUTICALS INC (RIGL)

rigel pharmaceuticals inc (RIGL) Related Businessweek News

No Related Businessweek News Found

rigel pharmaceuticals inc (RIGL) Details

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that intends to enter Phase III clinical trials for immune thrombocytopenic purpura and a Phase II clinical trial for immunoglobulin A nephropathy; R348, a topical janus kinase/SYK inhibitor in Phase II clinical trials for the treatment of keratoconjunctivitis sicca or chronic dry eye; R118, an adenosine monophosphate-activated protein kinase activator that intends to enter Phase I clinical trial; and two oncology product candidates in Phase I development. It also has small molecule discovery programs in muscle wasting. Rigel Pharmaceuticals, Inc. has collaboration agreement Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.

129 Employees
Last Reported Date: 03/4/14
Founded in 1996

rigel pharmaceuticals inc (RIGL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $551.7K
Co-Founder, Executive Vice President, Directo...
Total Annual Compensation: $559.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $521.3K
Compensation as of Fiscal Year 2013.

rigel pharmaceuticals inc (RIGL) Key Developments

Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) dropped from NASDAQ Biotechnology Index

Rigel Pharmaceuticals, Inc. will be removed from the NASDAQ Biotechnology Index.

Rigel Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:00 AM

Rigel Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Raul R. Rodriguez, Chief Executive Officer, President and Director.

Rigel Pharmaceuticals, Inc. Announces Executive Changes

Rigel Pharmaceuticals, Inc. announced James M. Gower is retiring from the board of directors and from his positions as chairman and chief executive officer, and Raul Rodriguez, most recently serving as the company's president and chief operating officer, will assume the position of chief executive officer and join the board of directors. Gary Lyons, a member of Rigel's Board of Directors since 2005, will become chairman. Mr. Gower is expected to remain an employee until the end of the year and, thereafter will be a consultant to the company providing advice on strategy, business development and other matters. Mr. Gower joined Rigel as president and chief executive officer in January 1997. He was named chairman of the board in October 2001. Under his guidance, Rigel grew from a small startup to a significant developer of small molecule therapeutics for a range of immune and metabolic disorders. Mr. Gower is a widely respected and well known leader in the biotech community, having previously served as president and chief executive officer of Tularik, Inc. (later acquired by Amgen), and as senior vice president at Genentech Inc. prior to its merger with Roche. Mr. Rodriguez joined Rigel in April 2000 as vice president of business development. He was named executive vice president and chief operating officer in June 2004, and has been president and chief operating officer since May 2010. In addition to overseeing the day-to-day operations of Rigel, Mr. Rodriguez has been pivotal in developing relationships with biopharmaceutical industry leaders and observers, speaking on behalf of the company and the industry at major events. Prior to joining Rigel, Mr. Rodriguez held senior management, business development and operations roles at Ontogeny, Inc. and Scios, Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RIGL:US $2.07 USD -0.08

RIGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.16 USD +0.01
CrystalGenomics Inc 12,950 KRW +350.00
CTI BioPharma Corp $2.20 USD +0.03
Exelixis Inc $1.87 USD -0.10
Progenics Pharmaceuticals Inc $5.98 USD -0.27
View Industry Companies
 

Industry Analysis

RIGL

Industry Average

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.6x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RIGEL PHARMACEUTICALS INC, please visit www.rigel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.